Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diisopropylamine dichloroacetate (DADA) is a small molecule salt composed of diisopropylamine and dichloroacetic acid, primarily used as a hepatoprotective agent for the treatment of chronic liver diseases such as fatty liver, hepatitis, and early-stage cirrhosis. Mechanistically, DADA acts as an inhibitor of pyruvate dehydrogenase kinase (PDK). By inhibiting PDK, it prevents the phosphorylation and subsequent inactivation of the pyruvate dehydrogenase complex (PDC), thereby promoting the aerobic oxidation of glucose and improving energy metabolism within hepatocytes. This metabolic modulation helps reduce intrahepatic lipid accumulation and supports liver cell regeneration. In China, it is manufactured and marketed by companies including Nanchang Hongyi Technology (Helioeast) in oral capsule and tablet formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diisopropylamine dichloroacetate.